Advertisement
ACT vs CGON
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACT is a Hold and CGON is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACT’s FA Score shows that 1 FA rating(s) are green whileCGON’s FA Score has 0 green FA rating(s).
- ACT’s FA Score: 1 green, 4 red.
- CGON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACT’s TA Score shows that 2 TA indicator(s) are bullish while CGON’s TA Score has 4 bullish TA indicator(s).
- ACT’s TA Score: 2 bullish, 6 bearish.
- CGON’s TA Score: 4 bullish, 3 bearish.
Price Growth
ACT (@Specialty Insurance) experienced а +0.58% price change this week, while CGON (@Biotechnology) price change was -1.50% for the same time period.
The average weekly price growth across all stocks in the @Specialty Insurance industry was +0.76%. For the same industry, the average monthly price growth was +0.91%, and the average quarterly price growth was -0.39%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.88%. For the same industry, the average monthly price growth was +14.10%, and the average quarterly price growth was +6.14%.
Reported Earning Dates
ACT is expected to report earnings on Aug 05, 2025.
CGON is expected to report earnings on Aug 07, 2025.
Industries' Descriptions
@Specialty Insurance (+0.76% weekly)Specialty insurance typically caters to niche-markets, and covers items that are special or unique and/or items that are not typically covered under other insurance policies. Restoration or purchase of a one-of-a-kind collector’s item, high-value home, recreational vehicles, sailboat or even jet skis, horses and farms, all-terrain vehicle, funerals, museums and fine art collections are some examples– one or more of which are covered by a specialty insurance provider. In some cases, a specialty insurance could also complement someone’s existing auto, home and umbrella policies. Markel Corp, for Fidelity National Financial, Inc., Assurant, Inc. and Athene Holding Ltd. are examples of specialty insurance providers.
@Biotechnology (+4.88% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ACT | CGON | ACT / CGON | |
| Capitalization | 4.96B | 2B | 249% |
| EBITDA | N/A | -95.94M | - |
| Gain YTD | 8.824 | -8.717 | -101% |
| P/E Ratio | 7.58 | N/A | - |
| Revenue | 1.15B | 684K | 168,713% |
| Total Cash | 5.9B | 541M | 1,091% |
| Total Debt | 745M | 296K | 251,689% |
ACT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 15 | |
SMR RATING 1..100 | 94 | |
PRICE GROWTH RATING 1..100 | 54 | |
P/E GROWTH RATING 1..100 | 44 | |
SEASONALITY SCORE 1..100 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ACT | CGON | |
|---|---|---|
| RSI ODDS (%) | N/A | 6 days ago 90% |
| Stochastic ODDS (%) | 1 day ago 73% | 2 days ago 88% |
| Momentum ODDS (%) | 1 day ago 57% | 2 days ago 78% |
| MACD ODDS (%) | 1 day ago 54% | 2 days ago 54% |
| TrendWeek ODDS (%) | 1 day ago 45% | 2 days ago 76% |
| TrendMonth ODDS (%) | 1 day ago 46% | 2 days ago 71% |
| Advances ODDS (%) | 1 day ago 63% | 2 days ago 74% |
| Declines ODDS (%) | 7 days ago 48% | 20 days ago 89% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 1 day ago 49% | N/A |
Advertisement
CGON and
Correlation & Price change
A.I.dvisor indicates that over the last year, CGON has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then IDYA could also see price increases.
| Ticker / NAME | Correlation To CGON | 1D Price Change % | ||
|---|---|---|---|---|
| CGON | 100% | -4.73% | ||
| IDYA - CGON | 60% Loosely correlated | -3.14% | ||
| SYRE - CGON | 57% Loosely correlated | -3.02% | ||
| ACLX - CGON | 57% Loosely correlated | -0.66% | ||
| KYMR - CGON | 54% Loosely correlated | -0.43% | ||
| KRYS - CGON | 54% Loosely correlated | +1.02% | ||
More | ||||